A 40-bp insertion/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population

Gene

Volumn 497, Issue 1, 2012, Pages 66-70

  Dong, Dong ^a   Gao, Xueren ^a   Zhu, Zhansheng ^a   Yu, Qiang ^b   Bian, Shizhong ^a   Gao, Yuzhen ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Indel polymorphism; MDM2; Rs3730485

Indexed keywords

ALPHA FETOPROTEIN; PROTEIN MDM2;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; FAMILY HISTORY; FEMALE; GENE DELETION; GENE INSERTION; GENOTYPE; HOMOZYGOTE; HUMAN; LIVER CELL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ALPHA-FETOPROTEINS; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDEL MUTATION; LECYTHIDACEAE; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK;

EID: 84862805847     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.01.004     Document Type: Article

References (26)

1. Bosch F.X., Ribes J., Díaz M., Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
2. Chen G.G., Ho R.L., Wong J., Lee K.F., Lai P.B. Single nucleotide polymorphism in the promoter region of human alpha-fetoprotein (AFP) gene and its significance in hepatocellular carcinoma (HCC). Eur. J. Surg. Oncol. 2007, 33:882-886.
3. Chen S., et al. An insertion/deletion polymorphism in the 3' untranslated region of beta-transducin repeat-containing protein (betaTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem. Biophys. Res. Commun. 2010, 391:552-556.
4. Cheng T.H., Cohen S.N. Human MDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops. Mol. Cell. Biol. 2007, 27:111-119.
5. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
6. Farinati F., et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am. J. Gastroenterol. 2006, 101:524-532.
7. Gao Y., et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 2009, 30:2064-2069.
8. Gillespie J.R., Uversky V.N. Structure and function of alpha-fetoprotein: a biophysical overview. Biochim. Biophys. Acta 2000, 1480:41-56.
9. Hu Z., et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int. J. Cancer 2006, 118:1275-1278.
10. Hussain S.P., Schwank J., Staib F., Wang X.W., Harris C.C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26:2166-2176.
11. Jin F., Xiong W.J., Jing J.C., Feng Z., Qu L.S., Shen X.Z. Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J. Cancer Res. Clin. Oncol. 2011, 137:1095-1104.
12. Liu G.Y., Jiang D.K., Shen S.Q., Yu L. MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis. Arch. Med. Res. 2011, 42:149-155.
13. Lu X., Ma O., Nguyen T.A., Jones S.N., Oren M., Donehower L.A. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007, 12:342-354.
14. Ma H., et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett. 2006, 240:261-267.
15. McClune A.C., Tong M.J. Chronic hepatitis B and hepatocellular carcinoma. Clin. Liver Dis. 2010, 14:461-476.
16. Michael D., Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 2003, 13:49-58.
17. Momand J., Zambetti G.P. Mdm-2: "big brother" of p53. J. Cell. Biochem. 1997, 64:343-352.
18. Moradpour D., Blum H.E. Pathogenesis of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2005, 17:477-483.
19. Nault J.C., Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin. Liver Dis. 2011, 31:173-187.
20. Staib F., Hussain S.P., Hofseth L.J., Wang X.W., Harris C.C. TP53 and liver carcinogenesis. Hum. Mutat. 2003, 21:201-216.
21. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 2002, 31:339-346.
22. Vargas D.A., Takahashi S., Ronai Z. Mdm2: a regulator of cell growth and death. Adv. Cancer Res. 2003, 89:1-34.
23. Walsh P.S., Metzger D.A., Higuchi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques 1991, 10:506-513.
24. Wilkening S., Bermejo J.L., Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007, 28:2262-2267.
25. Xiao Z.X., et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995, 375:694-698.
26. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92:725-734.